Joseph Jarabak

Isolation of two proteins with 9-ketoprostaglandin reductase and NADP-linked 15-hydroxyprostaglandin dehydrogenase activities and studies on their inhibition

Abstract Two proteins containing 9-ketoprostaglandin reductase and NADP-linked 15-hydroxyprostaglandin dehydrogenase activities have been isolated. Both of these activities are inhibited by a low molecular weight placental protein and by indomethacin, ethacrynic acid, and furosemide.

NADP-linked 15-hydroxyprostaglandin dehydrogenase from human placenta: Partial purification and characterization of the enzyme and identification of an inhibitor in placental tissue of an inhibitor in placental tissue

Abstract An NADP-linked 15-hydroxyprostaglandin dehydrogenase has been identified in human placental tissue and partially purified. Prostaglandins of the A and B series are good substrates for this enzyme while those of the E and F series are not. This enzymic preparation also catalyzes oxido-reductions at the 9 position of the prostaglandin molecule; these are slow compared to those occurring at the 15 position of the prostaglandins in the A and B series. Disc gel electrophoresis of the purified enzyme reveals the presence of three protein bands which contain dehydrogenase activity. Boiled placental homogenates contain an inhibitor which appears to be specific for the NADP-linked 15-hydroxyprostaglandin dehydrogenase. The inhibitor is heat stable and has a molecular weight of 6,000 – 7,000.

Polycyclic aromatic hydrocarbon quinone-mediated oxidation reduction cycling catalyzed by a human placental NADPH-linked carbonyl reductase

Polycyclic aromatic hydrocarbon quinones, hydroquinones, and glutathionyl adducts of quinones undergo oxidation-reduction (redox) cycling in the presence of NADPH and the NADPH-linked human placental carbonyl reductase. K-region and non-K-region o-quinones and their glutathione adducts are the best substrates of this enzyme; they are reduced to hydroquinones. Under aerobic conditions, the hydroquinones are autoxidized with the formation of potentially hazardous semiquinones and the superoxide anion. Because of these reactions it is unlikely that polycyclic aromatic hydrocarbon quinones or their glutathione adducts are inert products of detoxication in tissues that contain the carbonyl reductase or another enzyme with similar substrate specificity. If superoxide dismutase is added to reaction mixtures containing the carbonyl reductase and quinones, it inhibits redox cycling. Presumably this results from destruction of the superoxide anion which acts as a chain propagator in these reactions.

Substrate specificity of three prostaglandin dehydrogenases.

Studies on the substrate specificity, kcat/Km, and effect of inhibitors on the human placental NADP-linked 15-hydroxyprostaglandin dehydrogenase (9-ketoprostaglandin reductase) indicate that it is very similar to a human brain carbonyl reductase which also possesses 9-ketoprostaglandin reductase activity. These observations led to a comparison of three apparently homogeneous 15-hydroxyprostaglandin dehydrogenases with varying amounts of 9-ketoprostaglandin reductase activity: an NAD- and an NADP-linked enzyme from human placenta and an NADP-linked enzyme from rabbit kidney. All three enzymes are carbonyl reductases for certain non-prostaglandin compounds. The placental NAD-linked enzyme, which has no 9-ketoprostaglandin reductase activity, is the most specific of the three. Although it has carbonyl reductase activity, a comparison of the Km and kcat/Km for prostaglandin and non-prostaglandin substrates of this enzyme suggests that its most likely function is as a 15-hydroxyprostaglandin dehydrogenase. The results of similar comparisons imply that the other two enzymes may function as less specific carbonyl reductases.

Comparison of substrate specificities of the human placental NAD- and NADP-linked 15-hydroxyprostaglandin dehydrogenases

A study of the relative activity of the purified placental NAD- and NADP-linked 15-hydroxyprostaglandin dehydrogenases with various prostaglandins and thromboxane B2 (TxB2) suggests that most, if not all, oxidation in the placenta of the 15-hydroxyl group of prostaglandins of the A, E, and F series as well as PGI2 (prostacyclin) and 6-keto PGF1 alpha is catalyzed by the NAD-linked enzyme. Prostaglandin B1 is an excellent substrate for the NADP-linked enzyme. Despite the conformational similarities between PGB1 and PGI2, the latter molecule is a poor substrate for the NADP-linked enzyme. Thromboxane B2 is not oxidized by the NAD-linked enzyme and is oxidized slowly by the NADP-linked enzyme.

Early steps in prostaglandin metabolism in the human placenta

The activities of the enzymes catalyzing in the early steps in prostaglandin metabolism (the nicotinamide adenine dinucleotide [NAD]-linked 15-hydroxyprostaglandin dehydrogenase, the nicotinamide adenine dinucleotide phosphate [NADP]-linked 15-hydroxyprostaglandin dehydrogenase, and the 15-ketoprostaglandin delta 13 reductase) were measured in homogenates of term placenta. The NAD-linked enzyme possesses the highest activity of the three. The NADP-linked enzyme has much lower activity and probably acts physiologically as a 9-ketosprostaglandin reductase rather than as a 15-hydroxyprostaglandin dehydrogenase. Placental homogenates contain a low-molecular-weight, heat-stable inhibitor of the NADP-linked enzyme. The reaction catalyzed by the 15-ketoprostaglandin delta 13 reductase is the rate-limiting step. Analysis of the activity of these enzymes has shown that there is no significant relationship between them; furthermore, whether the placentas are from spontaneous single or twin deliveries, induced deliveries, or cesarean sections (in labor or not in labor) does not have a significant effect on the activity of the NAD- or NADP-linked dehydrogenases.

Purification and partial characterization of an NADH-linked Δ13-15-ketoprostaglandin reductase from human placenta

Abstract A Δ13-15-ketoprostaglandin reductase has been isolated from human placenta and purified 800-fold. The enzyme utilizes NADH as a cofactor but not NADPH. It reduces the 13,14 double bond in 15-ketoprostaglandin E1, E2 and F2α. The KM apparent for NADH is 54.8 μM and the KM apparent for 15-ketoprostaglanding E2 is 7.0 μM. The partially purified enzyme contains no 15-hydroxyprostaglandin dehydrogenase activity.

Kinetic studies on a 15-hydroxyprostaglandin dehydrogenase from human placenta.

Abstract Kinetic studies have shown that the reaction catalyzed by the human placental 15-hydroxyprostaglandin dehydrogenase proceeds by a single displacement mechanism. Addition of the reactants is ordered with NAD + binding first. The lifetime of the ternary complex is affected by the pH of the reaction mixture. At pH 7.0 a kinetically significant ternary complex is formed, while at pH 9.0 the ternary complex is not kinetically significant (Theorell-Chance mechanism). There is evidence for the occurrence of a kinetically significant isomerization of the enzyme · NADH complex at pH 9.0 but not at pH 7.0. At high substrate concentrations there is formation of unreactive complexes between the 15-hydroxyrostaglandin and both the free enzyme and enzyme · NADH complex and between the 15-ketoprostaglandin and both the free enzyme and enzyme · NAD + complex. The inhibition of the 15-hydroxyprostaglandin dehydrogenase by various prostaglandins and prostaglandin analogs may be explained by the formation of similar unreactive complexes. Certain prostaglandin analogs, arachidonic acid, and ethacrynic acid also affect the activity of the enzyme by causing its irreversible inactivation.

Redox cycling of polycyclic aromatic hydrocarbon o-quinones: metal ion-catalyzed oxidation of catechols bypasses inhibition by superoxide dismutase

Several two-electron quinone reductases catalyze the redox cycling of polycyclic aromatic hydrocarbon (PAH) o-quinones. When the carbonyl reductase of human placenta catalyzes the cycling of 9,10-phenanthrenequinone in aqueous phosphate buffer, reactive oxygen species are produced. Superoxide dismutase (SOD) inhibits the cycling by more than 90%, but the addition of 1 microM Cu2+ or 15 microM ferricytochrome c (cyt c3+) completely restores the cycling rate to that of the control. Similar results are obtained for 5,6-chrysenequinone, 5,6-benz[a]anthracenequinone, 4,5-benzo[a]pyrenequinone, and 7,8-benzo[a]pyrenequinone in assay mixtures which contain dimethyl sulfoxide. The 17beta-hydroxysteroid dehydrogenase (17beta-HSD) of human placenta also catalyzes the redox cycling of these quinones, and cycling is inhibited by SOD. Although free metal ions (Cu2+ and Fe3+) inhibit the 17beta-HSD, cyt c3+ does not inhibit the enzyme. If cyt c3+ is added to assay mixtures containing SOD, cycling rates are equal to those of the corresponding controls. These experiments suggest that SOD may not protect cells from the toxic effects of PAH o-quinone cycling if certain metal ions or metal chelates are also present.

Partial isolation and characterization of the 15-hydroxyprostaglandin dehydrogenases and 9-ketoprostaglandin reductases in rabbit kidney

Three types of 15-hydroxyprostaglandin dehydrogenase were identified in rabbit whole kidney homogenate when the centrifuged homogenate was sequentially fractionated by ammonium sulfate precipitation, DEAE-cellulose and Matrex Gel Blue A chromatographies, and Sephadex gel filtration. The first type is not adsorbed to DEAE-cellulose (peak 1). It catalyzes oxidoreduction of prostaglandins at both the C-15 and C-9 positions, is more active with NADP than NAD, is inhibited by indomethacin and ethacrynic acid, and migrates as three bands on disc gel electrophoresis. The second type is adsorbed to DEAE-cellulose (peak 2). It also migrates as multiple electrophoretic bands, has similar catalytic actions and co-factor requirements as the peak 1 enzyme and is inhibited by indomethacin and ethacrynic acid. A third type of 15-hydroxyprostaglandin dehydrogenase is also adsorbed to DEAE-cellulose but is partially separable from the other peak 2 enzymes on Matrex Gel Blue A and differs from those enzymes in preferentially oxidizing PGI2. It migrates as a single electrophoretic band and is also inhibited by indomethacin and ethacrynic acid.